10-Q: Ginkgo Bioworks Reports Q1 2025 Results, Revenue Increases Driven by BiomEdit Contract Termination

Ginkgo Bioworks' Q1 2025 revenue increased due to a one-time revenue recognition from the BiomEdit contract termination, while the company continues to manage restructuring and cost-saving initiatives.

Summary

• Ginkgo Bioworks Holdings, Inc. reported its financial results for the first quarter of 2025.
• Total revenue increased to $48.3 million, compared to $37.9 million in the same period of 2024.
• Cell Engineering revenue rose to $38.2 million, up from $27.9 million year-over-year, boosted by a $7.5 million non-cash revenue recognition from the BiomEdit contract termination.
• Biosecurity revenue remained relatively stable at $10.1 million.
• The company's net loss decreased to $91.0 million, compared to $165.9 million in Q1 2024.
• Research and development expenses decreased significantly to $70.9 million from $136.5 million year-over-year, reflecting restructuring efforts.
• General and administrative expenses also decreased to $49.0 million from $70.3 million in the prior year.
• The company incurred $5.3 million in restructuring charges related to its ongoing restructuring plan.
• Ginkgo Bioworks had cash, cash equivalents, and marketable securities totaling $516.9 million as of March 31, 2025.
• The company believes its current cash resources are sufficient to fund operations for at least the next 12 months.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While revenue increased and losses decreased, the company is still operating at a loss and faces ongoing restructuring challenges. The one-time revenue boost from the BiomEdit contract termination also raises questions about sustainable growth.

Positives

• Total revenue increased year-over-year, driven by Cell Engineering revenue.
• Net loss significantly decreased compared to the same period last year.
• Research and development expenses decreased, reflecting cost-saving measures.
• General and administrative expenses decreased, indicating improved operational efficiency.
• The company believes its current cash resources are sufficient to fund operations for at least the next 12 months.

Negatives

• The company continues to operate at a net loss.
• Interest income decreased due to lower average cash balances.
• The company incurred restructuring charges related to its ongoing restructuring plan.
• Loss on investments increased due to fluctuations in the stock prices of marketable equity securities.

Risks

• The company's expenditures are expected to exceed revenue for at least the next 12 months.
• The company is exposed to interest rate risk on its cash equivalents and marketable debt securities.
• The company is subject to foreign currency exchange rate risk from the translation of the financial statements of its foreign subsidiaries.
• The company's restructuring expenses related to potential asset impairments or contract amendments or terminations for any facilities no longer in use or underutilized could be material.

Future Outlook

The company believes its current cash resources are sufficient to fund operations for at least the next 12 months, as it continues its R&D activities, develops and expands its offerings, and potentially acquires and integrates companies, assets, or intellectual property.

Industry Context

Ginkgo Bioworks operates in the synthetic biology industry, which is characterized by intense competition and rapidly changing technology. The company's performance is influenced by its ability to convert potential customers to outsourced services, its reliance on customers to develop and manufacture products using engineered cells, and its ability to accurately predict customer demand.

Comparison to Industry Standards

• It's difficult to directly compare Ginkgo's results to industry standards due to its unique business model, which combines cell engineering services with downstream value sharing.
• Comparable companies in the contract research organization (CRO) space, such as Labcorp and Charles River Laboratories, typically generate revenue through service fees without significant downstream value share.
• In the biosecurity sector, companies like BioMerieux and QuidelOrtho focus on diagnostic products and services, which have different revenue models and growth drivers compared to Ginkgo's biomonitoring and bioinformatics services.
• Ginkgo's investments in platform ventures and structured partnerships are also unique, making direct comparisons challenging.

Related Party Transactions

• The company has significant transactions with related parties, primarily comprised of revenue-generating activities under collaboration and license agreements.
• In February 2025, the Company and Motif mutually agreed to terminate Motifs sublease of certain Company facility space whereby Motif paid the Company a termination fee of $1.6 million.
• In March 2025, the Company and BiomEdit mutually terminated certain agreements entered into in April 2022, which had granted BiomEdit a license to certain of the Companys intellectual property and established the terms under which the Company would provide technical research and development services to BiomEdit.

Stakeholder Impact

• Shareholders: The decrease in net loss is a positive sign, but the company's continued losses and reliance on one-time revenue gains may concern investors.
• Employees: The ongoing restructuring plan and workforce reductions may create uncertainty and impact employee morale.
• Customers: The company's focus on developing and expanding its offerings could benefit customers by providing new and improved services.
• Suppliers: The company's cost-saving measures and potential contract terminations may impact suppliers.
• Creditors: The company's sufficient cash resources to fund operations for at least the next 12 months is a positive sign for creditors.

Next Steps

• Continue R&D activities under existing and new programs.
• Further invest in the Foundry and Codebase.
• Develop and expand offerings.
• Upgrade, expand, or adapt operational, financial, and management systems.
• Potentially acquire and integrate companies, assets, or intellectual property.
• Maintain, expand, and protect intellectual property.
• Continue restructuring actions.

Key Dates

Keywords

revenue, biosecurity, cell engineering, financial results, Ginkgo Bioworks, restructuring, net loss, expenses